Abelacimab, formerly known as MAA868, represents a promising approach to managing thrombosis. This antithrombotic agent is a specific monoclonal immunoglobulin that inhibits the integrin αIIbβ3, a essential player in https://www.targetmol.com/compound/abelacimab